Video

Hank Fuchs, MD

Publish date: October 29, 2014

At the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit, Dr. Hank Fuchs, Chief Medical Officer at BioMarin Pharmaceuticals, discusses how industry thinking has evolved with regard to drug development for rare diseases.

 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

New Creutzfeldt-Jakob disease tests have high sensitivities, specificities
MDedge Neurology
New Daily Persistent Headache Is Often Associated With a Precipitating Event
MDedge Neurology
ALS Incidence Varies by Race and Ethnicity
MDedge Neurology
ALS ice bucket challenge: It’s hard to argue with success
MDedge Neurology
Autism sibling studies beginning to yield data
MDedge Neurology
Serum Albumin and Creatinine Levels May Indicate ALS Disease Severity
MDedge Neurology
New Tests May Accurately Detect Creutzfeldt–Jakob Disease
MDedge Neurology
Novel Drug May Help Patients With Narcolepsy Maintain Wakefulness
MDedge Neurology
Neurosarcoidosis Can Present a Clinical Challenge
MDedge Neurology
Marc Walton, MD, PhD
MDedge Neurology